Clinic for Nutrition and Obesity, ABC Medical Center, 116, Sur 136, Las Américas, Álvaro Obregón, 01120, Mexico City, Mexico.
Unidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Obes Surg. 2021 May;31(5):2087-2096. doi: 10.1007/s11695-021-05221-3. Epub 2021 Jan 19.
Cardiovascular disease (CVD) is highly prevalent in obese patients and is the leading cause of death. High levels of plasma low-density lipoprotein cholesterol (LDL-C) are associated with higher coronary artery disease (CAD) risk. The aim of the study was to assess the impact of the Roux-en-Y gastric bypass on the achievement of the currently proposed cardiovascular prevention goals after 1 year.
We performed a retrospective analysis from a prospectively built database of patients who underwent a primary Roux-en-Y gastric bypass (RYGB) from 2004 to 2018. Patients with intermediate, high, or very high risk for CVD according to the 2018 AHA/ACC or the 2019 ESC/EAS guidelines were selected. An analysis of clinical and biochemical variables in 1 year was performed. Logistic multivariate regressions were made to assess the impact of preoperative and weight loss parameters in the achievement of LDL-C goals.
From 1039 patients, 70 met the selection criteria and were included in the analysis of the 2018 AHA/ACC guidelines, and 75 in the 2019 ESC/EAS guidelines. Mean decrease in LDL-C levels was 21.1 ± 40.2 mg/dL 1 year after surgery, and 29/34 patients were off medications. The percentage of patients achieving LDL-C goals according to the 2018 AHA/ACC guidelines was 27.1%, whereas according to the 2019 ESC/EAS guidelines, the percentages was 9.3%. The %TWL was associated with achieving LDL-C goals according to the 2018 AHA/ACC at 1 year.
RYGB induces a significant weight loss and an improvement in LDL-C levels 1 year after surgery. The number of patients that reached the goals varies according to the guidelines used and ranged from 9.3 to 27.1%.
心血管疾病(CVD)在肥胖患者中高发,是死亡的主要原因。高水平的血浆低密度脂蛋白胆固醇(LDL-C)与更高的冠心病(CAD)风险相关。本研究旨在评估 1 年后 Roux-en-Y 胃旁路术对实现目前提出的心血管预防目标的影响。
我们对 2004 年至 2018 年间接受初次 Roux-en-Y 胃旁路术(RYGB)的患者进行了前瞻性数据库的回顾性分析。根据 2018 年 AHA/ACC 或 2019 年 ESC/EAS 指南,选择具有中等、高或极高 CVD 风险的患者。对术后 1 年的临床和生化变量进行了分析。进行了逻辑多元回归分析,以评估术前和体重减轻参数对 LDL-C 目标的影响。
在 1039 名患者中,70 名符合入选标准,被纳入 2018 年 AHA/ACC 指南的分析,75 名被纳入 2019 年 ESC/EAS 指南的分析。术后 1 年 LDL-C 水平平均下降 21.1±40.2mg/dL,29/34 名患者停药。根据 2018 年 AHA/ACC 指南,达到 LDL-C 目标的患者百分比为 27.1%,而根据 2019 年 ESC/EAS 指南,这一比例为 9.3%。1 年后,%TWL 与达到 2018 年 AHA/ACC 的 LDL-C 目标相关。
RYGB 术后 1 年可显著减轻体重,降低 LDL-C 水平。根据使用的指南,达到目标的患者比例从 9.3%到 27.1%不等。